Elina Hemminki

Last updated
Elina Hemminki
Born22 August 1948
Hausjärvi, Finland
NationalityFinnish
Alma mater University of Helsinki (MD)
University of Tampere (DrPH)
Occupation(s)Researcher, professor
Known forCritical innovative research

Kirsti Elina Hemminki (born 22 August 1948) is a Finnish academic who was trained in medicine and public health. She has wide research experience in health services and epidemiological research. Her research interests include use, determinants and consequences of medical technology, particularly in the field of preventive services. Many of her examples come from women's and children's health and drugs (medicines). Her interests include health services trials, and how ethical and governance rules apply to them. Her other research interests have included research policy and research regulation. [1]

Contents

Education

Hemminki graduated from a high school in Hyvinkää, Finland in 1967. She received her medical degree from the University of Helsinki (Licentiate of Medicine, MD) in 1973, and her DrPH, from the University of Tampere. She was a postdoctoral fellow in the Department of Health Services Administration, School of Public Health, the Johns Hopkins University, from 1976 to 1978.

Career

Hemminki started her research work while still a medical student. Her plans to combine research and clinical practice were ruined after realizing that combining these two with raising children was too much. Thus, since her graduation she has worked as a researcher and teacher in universities and research institutes, mainly in Finland. Her latest positions are a research professor in THL National Institute of Health and Welfare, [1] and an adjunct professor in public health at the University of Helsinki and Tampere University.

Hemminki's first research interests were physicians’ prescribing practices and medicine control, using psychotropic drugs as an example. Already in this early work she had particular interest in outside, particularly commercial forces, influencing physicians and the overutilization of medicines. The themes of physicians’ behaviour and commercial forces have been a thread of her research throughout her career.

Her plans to continue research on physicians’ drug prescribing changed in her postdoctoral studies in the US in 1977. For family reasons she was tied to Baltimore, and she started a new field, technology and reproductive health, which was more suitable to her study with Barbara Starfield in Johns Hopkins University. Working with Starfield, Hemminki did reviews on iron-prophylaxis and drugs against premature labor, using approaches which today would be called systematic reviews or meta-analyses. The reviews were made before electronic data searches of medical literature or the current methodology were available. The good local library was invaluable.

In 1979 Hemminki visited Oxford Perinatal Epidemiology Unit, then headed by Iain Chalmers, at the time when the idea of evidence-based medicine and systematic reviews was developed. Even though she did not become an active member of Cochrane Collaboration, later rising from the ideas in Oxford, the critical thinking and ways of approaching the value of individual health technologies were important for her later work. She was active in various international networks, including ISTAHC (International society of technology assessment in health care), later transformed into Health Technology Assessment International (HTAi). [2]

Besides systematic reviews, Hemminki's other tools to critically examine the use of health technology were area variation as well as comparing the scientific evidence with the actual practice. She has also had a great interest to adapt the methods of randomized trials to evaluate health services (health services trials). [3] Other methodological interests Elina Hemminki has had include use of administrative health registers in research. [4]

Many of Hemminki's research focused on reproduction, first pregnancy and birth, and later more broadly, menopause. The interest in menopause started in a research visit to John and Sonja McKinley's research unit in Boston in 1987, later known as the New England Research Institutes, which at the time had interest in menopause. That was the time of a hot debate of the benefits of hormone replacement therapy (HRT), mainly based on non-experimental data. The subsequent study in Finland on the menopause as a health service question, widened into involvement into study and debate on health effects of HRT. [5] That interest produced a number of important publications, including the selection bias to HRT and the use of non-public documents of drug control authorities to study adverse effects of drugs. [6] The interest led also to a small trial in Estonia, originally planned to be part of a large WISDOM study. [7]

The work with HRT health effects concretely showed what it was like to have a varying view with local establishment, as well as the needs and working habits of media. This experience activated Hemminki's old interest in commercial factors influencing physicians and conflict of interests (COI). In her 1977 paper in Social Science & Medicine, Hemminki had empirically showed that many Finnish key-physicians had associations with drug industry. [8] The potential consequences of such close collaboration include merging of the interest of commercial actors, particularly drug industry, and medical establishment, and confusing the voice of the scientific world. This is likely to have adverse effects on medical practice and health policy.

The large role of the commercial actors in funding health research, hinders on evidence-based medicine, as well as the dominance of drug research and its paradigms in regulation of medical research contributed to Hemminki's interest to study medical research and its regulation. [1] This work has shown that the current regulation prevents health services trials and other “non-traditional” designs, and is a hinder to evidence based health care. Her research has also contributed to illustrate an important element in the distortion of knowledge: publication bias and secrecy around commercial studies.

Most of Hemminki's scientific production is in English, and available through scientific literature databases, such as PubMed. Policy-oriented papers meant for domestic professionals and lay-people are mainly in Finnish. Her empirical research work has mainly data from developed countries. But her work in China and Mozambique showed that many of the questions of health technology and health services are the same in poorer countries, and often clearer to observe. [1]

Personal

Elina has three adult children and six grandchildren.[ citation needed ]

Hemminki has supervised and mentored a number of younger researchers, who later have had successful careers either in research or in health administrative positions. Elina Hemminki has had various positions of trust in scientific and administrative bodies, including expert positions in the Academy of Finland. She has been active in many professional and other NGOs, including Health Action International (HAI) [9] and Finnish NGO Physicians for Social Responsibility. [10]

Related Research Articles

<span class="mw-page-title-main">Medicine</span> Diagnosis, treatment, and prevention of illness

Medicine is the science and practice of caring for a patient, managing the diagnosis, prognosis, prevention, treatment, palliation of their injury or disease, and promoting their health. Medicine encompasses a variety of health care practices evolved to maintain and restore health by the prevention and treatment of illness. Contemporary medicine applies biomedical sciences, biomedical research, genetics, and medical technology to diagnose, treat, and prevent injury and disease, typically through pharmaceuticals or surgery, but also through therapies as diverse as psychotherapy, external splints and traction, medical devices, biologics, and ionizing radiation, amongst others.

<span class="mw-page-title-main">Clinical trial</span> Phase of clinical research in medicine

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.

Hot flashes are a form of flushing, often caused by the changing hormone levels that are characteristic of menopause. They are typically experienced as a feeling of intense heat with sweating and rapid heartbeat, and may typically last from two to 30 minutes for each occurrence.

<span class="mw-page-title-main">Rosalyn Sussman Yalow</span> American medical physicist

Rosalyn Sussman Yalow was an American medical physicist, and a co-winner of the 1977 Nobel Prize in Physiology or Medicine for development of the radioimmunoassay technique. She was the second woman, and the first American-born woman, to be awarded the Nobel Prize in Physiology or Medicine.

Bioidentical hormone replacement therapy (BHRT), also known as bioidentical hormone therapy (BHT) or natural hormone therapy, is the use of hormones that are identical on a molecular level with endogenous hormones in hormone replacement therapy. It may also be combined with blood and saliva testing of hormone levels, and the use of pharmacy compounding to obtain hormones in an effort to reach a targeted level of hormones in the body. A number of claims by some proponents of BHT have not been confirmed through scientific testing. Specific hormones used in BHT include estrone, estradiol, progesterone, testosterone, dehydroepiandrosterone (DHEA), and estriol.

<span class="mw-page-title-main">Medical research</span> Wide array of research

Medical research, also known as experimental medicine, encompasses a wide array of research, extending from "basic research", – involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials. Within this spectrum is applied research, or translational research, conducted to expand knowledge in the field of medicine.

<i>PLOS Medicine</i> Academic journal

PLOS Medicine is a peer-reviewed weekly medical journal covering the full spectrum of the medical sciences. It began operation on October 19, 2004, as the second journal of the Public Library of Science (PLOS), a non-profit open access publisher. All content in PLOS Medicine is published under the Creative Commons "by-attribution" license. To fund the journal, the publication's business model requires in most cases that authors pay publication fees. The journal was published online and in a printed format until 2005 and is now only published online. The journal's acting chief editor is Clare Stone, who replaced the previous chief editor, Larry Peiperl, in 2018.

<span class="mw-page-title-main">Marcia Angell</span> American physician and academic (born 1939)

Marcia Angell is an American physician, author, and the first woman to serve as editor-in-chief of the New England Journal of Medicine. She is currently a Senior Lecturer in the Department of Global Health and Social Medicine at Harvard Medical School in Boston, Massachusetts.

Dame Valerie Beral AC DBE FRS FRCOG FMedSci was an Australian-born British epidemiologist, academic and a preeminent specialist in breast cancer epidemiology. She was Professor of Epidemiology, a Fellow of Green Templeton College, Oxford and was the Head of the Cancer Epidemiology Unit at the University of Oxford and Cancer Research UK from 1989.

Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause. Effects of menopause can include symptoms such as hot flashes, accelerated skin aging, vaginal dryness, decreased muscle mass, and complications such as osteoporosis, sexual dysfunction, and vaginal atrophy. They are mostly caused by low levels of female sex hormones that occur during menopause.

Patient participation is a trend that arose in answer to medical paternalism. Informed consent is a process where patients make decisions informed by the advice of medical professionals.

Medical ghostwriters are employed by pharmaceutical companies and medical-device manufacturers to produce apparently independent manuscripts for peer-reviewed journals, conference presentations and other communications. Physicians and other scientists are paid to attach their names to the manuscripts as though they had authored them. The named authors may have had little or no involvement in the research or writing process.

<span class="mw-page-title-main">JoAnn E. Manson</span> American physician

JoAnn Elisabeth Manson is an American physician and professor known for her pioneering research, public leadership, and advocacy in the fields of epidemiology and women's health.

<span class="mw-page-title-main">Anne MacGregor</span> British doctor

Anne MacGregor is a New Zealand-born British medical researcher and clinician based in London. She is a leading researcher in the field of hormonal effects on migraine.

<span class="mw-page-title-main">Maryon Stewart</span> British author and broadcaster

Maryon Stewart is a British author and broadcaster known for her work in the field of non-drug medicine. Specialising in educating and coaching women in how to control menopause symptoms without hormone replacement therapy (HRT), she is sometimes referred to as a pioneer of the "Natural Menopause Movement".

Penny Wise Budoff was an American physician. She was a family practitioner, and a clinical associate professor of family medicine at the State University of New York at Stony Brook. She is known for her research, which established that menstrual cramping is a physical phenomenon rather than a psychological one. She wrote two books on women's health.

Kathleen I. Pritchard, is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, specializing in breast cancer therapies, and leading the clinical trials division of the centre. She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology. According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.

<span class="mw-page-title-main">Alastair MacLennan (obstetrician)</span> Scottish-Australian physician, researcher, and health advocate (born 1945)

Alastair Harvey MacLennan,, MB ChB, MD, FRCOG, FRANZCOG is a Scottish-Australian physician, professor of obstetrics and gynaecology, medical researcher, and a community health advocate. He studied and practised medicine in Glasgow, Chicago, and Oxford before moving to Australia in 1977 to take up a position at the University of Adelaide, where he went on to become the Professor and Head of the Discipline of Obstetrics and Gynaecology in 2006. He retired from his full-time academic position in 2013, and he is now Emeritus Professor of Medicine. He leads research projects at the Robinson Research Institute, and he is Head of the university's Cerebral Palsy Research Group.

Valerie Montgomery Rice is an American obstetrician, gynecologist, and college administrator. She is the president and dean of Morehouse School of Medicine.

<span class="mw-page-title-main">Emily Banks</span> Epidemiologist and public health researcher

Emily Banks is an Australian epidemiologist and public health physician, working mainly on chronic disease. She is a Professor of Epidemiology and Public Health and Head of the Centre for Public Health Data and Policy at the Australian National University, and a visiting professor at the University of Oxford.

References

  1. 1 2 3 4 "Elina Hemminki". National Institute for Health and Welfare. 23 Nov 2014. Retrieved 19 Apr 2015.
  2. ↑ "Home". Health Technology Assessment international. 2015. Retrieved 19 Apr 2015.
  3. ↑ Hakama, M; Malila, N; Dillner, J (2012). "Randomised health services studies". Int J Cancer. 131 (12): 2898–2902. doi: 10.1002/ijc.27561 . PMID   22461063.
  4. ↑ Gissler, M; Hemminki, E; Louhiala, P; Järvelin, MR (1998). "Health registers as a feasible means of measuring health status in childhood—a 7-year follow-up of the 1987 Finnish birth cohort". Paediatr Perinat Epidemiol. 12 (4): 437–455. doi:10.1046/j.1365-3016.1998.00126.x. PMID   9805716.
  5. ↑ McPherson, K; Hemminki, E (2004). "Synthesising licensing data to assess drug safety". BMJ. 328 (7438): 518–520. doi:10.1136/bmj.328.7438.518. PMC   351857 . PMID   14988197.
  6. ↑ Hemminki, E; McPherson, K (2000). "Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease". Lancet. 355 (9203): 566–569. doi:10.1016/s0140-6736(99)03432-7. PMID   10683020. S2CID   44994747.
  7. ↑ Veerus, P; Hovi, SL; Fischer, K; Rahu, M; Hakama, M; Hemminki, E (2006). "Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]". Maturitas. 55 (2): 162–173. doi: 10.1016/j.maturitas.2006.01.012 . PMID   16504428.
  8. ↑ Hemminki, E; Pesonen, T (1977). "An inquiry into associations between leading physicians and the drug industry in Finland". Soc Sci Med. 11 (8–9): 501–506. doi:10.1016/0037-7856(77)90027-0. PMID   929241.
  9. ↑ "Health Action International". Health Action International. 2015. Retrieved 3 May 2015.
  10. ↑ "Lääkärin Sosiaalinen Vastuu". Lääkärin Sosiaalinen Vastuu (Physicians for Social Responsibility). 2015. Retrieved 3 May 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.